Vor Biopharma Inc. (VOR)

US — Healthcare Sector
Peers: GRCL  THRX  GLUE  DSGN  ERAS  EWTX  TALS  ACET  CGEM  NUVL  VTYX  ACLX  KNSA  BOLT  DAWN  LYRA  AUTL  FHTX  STTK  KYMR  NRIX 

Automate Your Wheel Strategy on VOR

With Tiblio's Option Bot, you can configure your own wheel strategy including VOR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VOR
  • Rev/Share 0.0
  • Book/Share 0.5293
  • PB 0.344
  • Debt/Equity 0.4659
  • CurrentRatio 3.8768
  • ROIC -1.2516

 

  • MktCap 22755216.0
  • FreeCF/Share -0.806
  • PFCF -0.2262
  • PE -0.1917
  • Debt/Assets 0.2816
  • DivYield 0
  • ROE -1.4213

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
VOR
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.

Read More
image for news Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
VOR
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials.

Read More
image for news Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

About Vor Biopharma Inc. (VOR)

  • IPO Date 2021-02-05
  • Website https://www.vorbio.com
  • Industry Biotechnology
  • CEO Dr. Robert Ang M.B.A., M.D., MBBS
  • Employees 159
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.